Ignite Creation Date:
2024-05-05 @ 9:48 PM
Last Modification Date:
2024-10-26 @ 10:09 AM
Study NCT ID:
NCT00960349
Status:
COMPLETED
Last Update Posted:
2011-06-14
First Post:
2009-08-11
Brief Title:
Study of Cediranib Plus Cisplatin Plus CapecitabineS-1 in Japanese Gastric Cancer Patients
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase I Open-label Non-randomized Study to Assess the Safety and Tolerability of Cediranib AZD2171 in Combination With Cisplatin Plus a Fluoropyrimidine Capecitabine or S-1 in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to assess the safety and tolerability of cediranib in combination with Cisplatin plus a Fluoropyrimidine Capecitabine or S-1 in Japanese patients with previously untreated locally advanced or metastatic unresectable gastric cancer GC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None